These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26884249)

  • 1. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
    Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
    Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
    Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
    J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
    Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
    Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Horm Metab Res; 2013 Jun; 45(6):408-14. PubMed ID: 23386415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
    Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of nutraceuticals on anaplastic thyroid cancer cells.
    Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
    Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
    Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
    Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 15. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
    Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
    Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.